

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.usplo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/568,081	02/13/2006	Zhong Chao Yin	2577-160	6297
6449	7590 10/10/2006		EXAMINER	
ROTHWELL, FIGG, ERNST & MANBECK, P.C. 1425 K STREET, N.W. SUITE 800 WASHINGTON, DC 20005			ZHENG, LI	
			ART UNIT	PAPER NUMBER
			1638	
			DATE MAILED: 10/10/200	6

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)					
Office Action Summary		10/568,081	YIN ET AL.					
		Examiner	Art Unit					
		Li Zheng	1638					
Period fo	The MAILING DATE of this communication a or Reply	ppears on the cover shee	et with the correspondence a	address				
WHIC - Exte after - If NC - Failu Any	ORTENED STATUTORY PERIOD FOR REP CHEVER IS LONGER, FROM THE MAILING nsions of time may be available under the provisions of 37 CFR SIX (6) MONTHS from the mailing date of this communication. O period for reply is specified above, the maximum statutory perious are to reply within the set or extended period for reply will, by state reply received by the Office later than three months after the mailed patent term adjustment. See 37 CFR 1.704(b).	DATE OF THIS COMMU 1.136(a). In no event, however, mo od will apply and will expire SIX (6) tute, cause the application to become	JNICATION. ay a reply be timely filed MONTHS from the mailing date of this ne ABANDONED (35 U.S.C. § 133).	`				
Status								
1)[🛛	Responsive to communication(s) filed on 13	February 2006.						
2a)□	_	nis action is non-final.						
3)	, 							
	closed in accordance with the practice under	r Ex parte Quayle, 1935	C.D. 11, 453 O.G. 213.					
Disposit	ion of Claims							
4)🖂	4) Claim(s) 1-8,11-13,16,17 and 19-24 is/are pending in the application.							
, —	4a) Of the above claim(s) is/are withdrawn from consideration.							
5)	Claim(s) is/are allowed.	•						
6)	Claim(s) is/are rejected.							
7)	Claim(s) is/are objected to.							
8)🖂	Claim(s) <u>1-8,11-13,16,17 and 19-24</u> are subj	ject to restriction and/or	election requirement.					
Applicat	ion Papers							
9)[The specification is objected to by the Exami	ner.						
10)	The drawing(s) filed on is/are: a) a	ccepted or b) dbjected	I to by the Examiner.					
	Applicant may not request that any objection to the	ne drawing(s) be held in abo	eyance. See 37 CFR 1.85(a).					
	Replacement drawing sheet(s) including the corre	ection is required if the drav	ving(s) is objected to. See 37	CFR 1.121(d).				
11)	The oath or declaration is objected to by the	Examiner. Note the attac	ched Office Action or form F	PTO-152.				
Priority ι	under 35 U.S.C. § 119							
·—	Acknowledgment is made of a claim for foreion All b) Some * c) None of:	gn priority under 35 U.S.	C. § 119(a)-(d) or (f).					
,	1. Certified copies of the priority docume	nts have been received.						
	2. Certified copies of the priority documents have been received in Application No							
	3. Copies of the certified copies of the priority documents have been received in this National Stage							
	application from the International Bure	eau (PCT Rule 17.2(a)).						
* 5	See the attached detailed Office action for a li	st of the certified copies	not received.					
			·					
Attachmen	t(s)							
	e of References Cited (PTO-892)	4) 🔲 Intervi	ew Summary (PTO-413)					
- =	be of Draftsperson's Patent Drawing Review (PTO-948)		No(s)/Mail Date of Informal Patent Application					
	mation Disclosure Statement(s) (PTO/SB/08) er No(s)/Mail Date		or informal Patent Application	•				

DETAILED ACTION

Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1, 3, 5, 11-13, and 22, drawn to a nucleotide sequence that confers resistance to *Xanthomonas* and the genetic vector containing said nucleotide sequence.

Group II, claims 2, 4, 6-8, 16-17, 19-21 and 23-24, drawn to a method of enhancing resistance to *Xanthomonas* and the transgenic plant/cell produced.

The inventions listed as Groups I-II do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The technical feature linking the inventions of Groups I-II is a nucleotide sequence that confers resistance to *Xanthomonas*. However, such a nucleotide sequence is anticipated by Zhang et al (1999, *Nature Biotech*. 17:1021-1024). Wang et

al. teach that transgenic sugarcane plants expressing an *albD* gene can confer a high level of resistance to symptom induction, and multiplication and systemic invasion by *Xanthomonas albilineans* (page 1021, the 3rd paragraph of the left column). Therefore this technical feature does not constitute a special technical feature as defined by PCT Rule 13.2, because it does not define a contribution over the prior art.

Applicants are reminded that different nucleotide sequences and amino acid sequences are structurally distinct chemical compounds and are unrelated to one another. These sequences are thus deemed to normally constitute different inventive concepts.

For invention Group I-II above, restriction to one of the nucleotide sequences of SEQ ID NO: 1-4 and 49-52 or polypeptide sequence of SEQ ID NO: 5 is also required.

Claims that do not read on the elected nucleotide sequence or polypeptide sequence will be considered withdrawn. Applicant is advised that a reply to this requirement must include an identification of the nucleotide sequence or polypeptide sequence that is selected. An election that does not identify the nucleotide sequence or polypeptide sequence will be considered nonresponsive. This requirement is not to be construed as a requirement for an election of species, since each nucleotide and amino acid sequence is not a member of single genus of invention, but constitutes an independent and patentably distinct invention.

Application/Control Number: 10/568,081 Page 4

Art Unit: 1638

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Li Zheng whose telephone number is 571-272-8031. The examiner can normally be reached on Monday through Friday 9:00 AM - 5:30 PM EST.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anne Marie Grunberg can be reached on 571-272-0975. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

ASH**WIN D. MEHTA, PH.D.** P**rimary.examiner** Application/Control Number: 10/568,081

Art Unit: 1638

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Page 5